CA1229551A - Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration - Google Patents
Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administrationInfo
- Publication number
- CA1229551A CA1229551A CA000469018A CA469018A CA1229551A CA 1229551 A CA1229551 A CA 1229551A CA 000469018 A CA000469018 A CA 000469018A CA 469018 A CA469018 A CA 469018A CA 1229551 A CA1229551 A CA 1229551A
- Authority
- CA
- Canada
- Prior art keywords
- weight
- sustained release
- release pharmaceutical
- carrier
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
ABSTRACT OF THE DISCLOSURE
A novel pharmaceutical composition is disclosed.
It comprises a sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
A novel pharmaceutical composition is disclosed.
It comprises a sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
Description
~L2Z955~
METHOD AND COMPOSITION FOR THE PREPARATION
OF CONTROLLED LONG-ACTING PHARMACEUTICALS
FOR ORAL ADMINISTRATION
This invention relates to a novel controlled long-acting dry pharmaceutical composition using a carrier or base material in admixture with an effective amount of a therapeutic agent or medicament. The unique composition of the base materials can be used for "one-a-day" controlled release tablets of zero order containing various medicaments. The sustained release composition can be formed into a lozenge, tablet or suppository. Because of its properties, the composition can also be used as a base composition in tablets fox biaxial administration.
BACKGROUND OF THE INVENTION
The advantages of long-acting or sustained release products are well-known. Such products are of great value in the pharmaceutical field because medication can be administered for uniform and continuous release over a prolonged period of time to achieve a stable and desired blood level of the active ingredient without requiring frequent administration of the medicamentO The sustained release composition must meet certain criteria, namely it must provide uniform and constant dissolution and efficacy for a prolonged period of time, it must be easy to prepare, it must have acceptable taste and must be adaptable for use with a variety of therapeutic agents.
The use of cellulosic materials such as hydroxypropyl methyl cellulose as an ingredient in pharmaceutical formulations is known. For example, .
Z2~S5~
US. Patent No. 3,590,117 describes the use of hydroxypropyl methyl cellulose in long lasting torches used as vehicles for administering active medicaments. US. Patent No.
3,870,790, describes mixing an active therapeutic ingredient with a copolymer of premoisturized hydroxypropyl methyl cellulose powder optionally mixed with ethyl cellulose powder. The release period of the active medicament is a function of the moisture content of the cellulose carrier.
In US. Patent No. 4,259,314 there is described compositions which employ hydroxypropyl methyl cellulose of different viscosity grades and hydroxypropyl cellulose in a dry powder composition which has particular value for use with hydroscopic active ingredients.
US. Patent No. 4,292,299 to Suzuki et at.
describes a long-acting biaxial preparation which includes an adhesive outer layer comprising polymers which have adhesiveness to a wet mucous surface and which swell upon moistening together with a nonadhesive layer which is water soluble or water disintegrable. At least one of the layers is made to contain the active ingredient. The polymers suggested for use in the adhesive layer include homopolymers of acrylic acid monomers such as polyacrylic acid and related salts.
None of the compositions described in the prior art have demonstrated completely satisfactory properties for the administration of large active ingredient molecules. In particular the prior art compositions have not satisfactorily solved the problem of administering such molecules via resorption from the composition in the biaxial I
~Z2~55~
pouch of the mouth. Nor have the prior art compositions demonstrated completely satisfactory characteristics where it is desired to administer active ingredients over a 12 to 24 hour time period.
OBJECTS OF THE INVENTION
_ It is accordingly an object of the invention to provide a controlled, long-acting pharmaceutical composition for effective administration of therapeutic agents.
It is another object of the invention to provide a new base material or carrier which can be used in admixture with a variety of therapeutic agents and which can also be easily and inexpensively manufactured.
It is a further object to provide a method for producing a controlled, long-acting pharmaceutical composition which can be used for administering large active ingredient molecules.
It is still a further object of the invention to provide a method and composition for preparing a sustained release pharmaceutical formulation which can be used to administer large molecules of active ingredient via the biaxial pouch of the mouth.
It is yet a further object of the invention to provide a method and composition for preparing a sustained release pharmaceutical formulation which can be used to administer active ingredients over a 12 to 24 hour time frame, i.e., a so-called "zero order" sustained release composition.
us Other objects of the invention will be apparent from the following discussion.
GENERAL DESCRIPTION
These and other objects of the invention are achieved by using a carrier prepared from at least three components. Broadly, the carrier is comprised of:
(a) 5.5-98.5~ by weight of hydroxypropyl methyl cellulose;
(b) 0.25-4.5~ by weight of : hydroxypropyl cellulose; and (c) 1-90% by weight of a carboxyvinyl polymer.
Desirably, the carrier is comprised of:
(a) 10-80~ by weight of hydroxypropyl methyl cellulose;
(b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75~ by weight of a carboxyvinyl polymer.
In preferred form the carrier is comprised of:
(a) 2-35% by weight of hydroxypropyl methyl cellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20C;
(b) 3-85% by weight of hydroxypropyl methylcellulvse having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20C; and 12~gSSl (c) 2-40~ by weight of hydroxypropyl methyl cellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20 C;
(do 0.5-40~ by weight of hydroxpropyl methyl cellulose having a viscosity of about 100,000 centipoise for a I aqueous solution at 20 C;
(e) 0.25 to 4.5% by weight of hydroxypropyl cellulose; and f) 1 to 90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0~ by weight neutralized solution.
Preferably the hydroxypropyl cellulose which is used has a viscosity of 1000 to 4500 when measured as a 2% by weight aqueous solution.
Hydroxypropyl methyl cellulose having viscosities of 50 and 4000 centipoise for I aqueous solutions at 20C
are known and commercially available as Methuselah Eye and EM respectively (Dow Chemical Company registered trademarks). Hydroxypropyl methyl cellulose having viscosities of 15,000 and 100,000 centipoise for I aqueous solutions at 2Q C are known and commercially available as Methuselah K-15M and Loom respectively (Dow Chemical Company registered trademarks). Hydroxypropyl cellulose as used in accordance with the invention is known and commercially available as Closely (a Hercules Inc. registered trademark).
~ZZ~S5~
The carboxyvinyl polymers used in the invention are acrylic acid polymers cross linked with a polyalkenyl polyether. The polymers are available from the BY Goodrich Company under the trademark Carbopol. They have viscosities of 30,000-40,000 centipoise for 3% aqueous solutions. The polymer is a weak acid and reacts to form salts. Therein lies their efficacy in providing 2 zero order release rate under the alkaline conditions found in the small intestine.
The mixtures of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and polyacrylic acid are prepared in a straightforward method. The several components are added in the desired proportions to one another and thoroughly mixed to form a uniform composition. Thereafter from 2 to 700 my of an active ingredient are added to the carrier and the pharmaceutical composition is compressed and shaped into a convenient pharmaceutical form. Depending upon the conditions under which the material is compressed and further depending on the relative proportions of the several components, one obtains a product of unique sustained release characteristic. The sustained release characteristic of the composition can be predetermined and varied by adjusting the makeup of the composition within the aforesaid limits and/or by adjusting the compression of the tablet.
If the pharmaceutical composition is compressed under low pressure, a trash or biaxial tablet can be prepared capable of being sucked or used in the mouth. A
controlled release of the active therapeutic agent which is -~2;~955~
mucosally absorbed into the blood stream is achieved. If higher pressures are used to compress the pharmaceutical material a harder and longer-lasting pharmaceutical composition can be prepared suitable for rectal or vaginal application or suitable for swallowing in the form of a tablet. The final products may additionally contain adjutants such as coloring agents, flavoring agents, synthetic sweetening agents and preservatives.
To make the absorption of large molecules through the biaxial pouch possible, a sweetening agent like saccharin, cyclamate, Aspartame, or any other chemical which is at least 30 times as sweet as sugar is added to the base material in a quantity of 2 my or more.
The pharmaceutical compositions obtained using the dry carrier base material of the invention have controlled, long-acting capability so that therapeutically active agents can be uniformly and continuously released over prolonged periods of time ranging from about 2 to 24, or more, hours.
The duration, uniformity and continuity of release Or the therapeutically active ingredient can be suitably controlled by varying the relative amounts of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and carboxyvinyl polymer and/or by changing the surface of the finished product. The dry pharmaceutical formulation of the invention has considerable flexibility and versatility depending upon the form in which it is administered and the particular nature of the active therapeutic agent combined with the dry carrier base material.
~Z29SS~
Examples In each of the following examples the carrier composition defined was prepared by mixing the several components in the desired proportion in a mixing bowl. The mixture was thoroughly stirred to achieved uniformity and thereafter the desired amount of active ingredient and other adjutants were added in the amounts indicated.
The carrier, excipients and active ingredients were then thoroughly mixed and thereafter compressed into tablets at a compression of from 6 to 10 kg./cm2.
Base Composition Weight in Percent EX~lPLE I
Pseudephedrine Hal 120 my E-4M55 my 73.3333%
K-15M15 " 20.0000%
Closely 3 " 4.0000%
Carbopol 2 " 2.6667%
EXAMPLE II
-Hexocyclium methyl sulfate 50 my E-4M42.5 ") K-15M5.0 ") 98.5%
K-100~1 1.75 ") Carbopol .5 lo Closely . 25 " 0.5%
~955~l Base Composition Weight in Percent EXAMPLE III
Procainamide HCL250 my E-5012.5 " 9.6525%
EM 80 " 61.7761%
K-15M 30 " 23.1660%
Carbopol 5 n 3.8610%
Closely " 1.5444%
EXAMPLE IV
Ethaverine HCL150 my K-15M 6.75 " 4.5%
Clime " 1.0%
Carbopol 135 " 90.0~
Closely n 4.5%
EXAMPLE V
Imipramine HCL50 my EM 30 " 52.6316%
Clime 15 l 26.3158%
Carbopol10 " 17.5438 Closely 2 " 3.5088 EXAMPLE VI
Ferrous fumarate320 my K-15M 120 " 69.3641 Lomb 25 " 14.4509%
Xlucel 3 " 1.7341~
Carbopol 25 " 14.4509%
_ g _ of I
Base Composition Weight in Percent EXAMPLE VII
-Dextrometorphan BRIE 15 my (lozenge) E-4M13.5 3.8849%
Minutely Hexanitrate 320 "92.0863~
Carbopol 13.5 " 3.8849%
Closely 0.5 " 0.1439%
EXAMPLE VIII
Hydralazine HAL 100 my E-4M75 " 72.1154%
Clime 20 " 19.2308%
Closely 4 " 3.8461%
Carbopol 5 " 4.8077%
: EXAMPLE IX
Indomethacin75 my E-4M40 " 53.33%
X-15M 25 n 33.33~
Closely 3 " 4.00%
Carbopol 7 " 9,33%
~ZZ~55~
Base Composition Weight in Percent EXAMPLE X
_ - Meprobamate 400 my E-5070 " 34.3137%
X-15M80 " 39.2157 Clime 30 " 14,7059%
Carbop~l 20 " 9.8039%
Closely 4 " 1.9608%
EXAMPLE XI
SecGbarbital sodium 200 my (suppositories) K-15M130 " 19.9386%
Loom 80 " 12.2700%
Carbopol 40 " 6.1350%
Lucille 2 " .3067%
Excipients 400 " 61.3497%
EXAMPLE XII
Phenylpropanola~ine 75 my E-4M30 " 38.4615%
R-15M20 " 25.6410~
Clime 10 " 12.8205%
Carbopol 15 n 19.2308%
Closely 3 " 3.8462%
The novel carriers of the invention can be used with a wide variety of active therapeutic agents. The ~L~2~335Sl improved long acting compositions can be used, without limitation, as cardiovascular anti-inflammatories, analgesics, antiarrhymetics, bronchodilators, tranquilizers, calcium blockers, beta-blockers, decongestants, antispasmodic, weight control, antacids, cold and allergy products, and sedatives. It will be well understood by those skilled in the art that certain equivalents of each as shown may be employed and it will be recognized that various modifications are possible within the scope of the invention as defined in the following claims.
METHOD AND COMPOSITION FOR THE PREPARATION
OF CONTROLLED LONG-ACTING PHARMACEUTICALS
FOR ORAL ADMINISTRATION
This invention relates to a novel controlled long-acting dry pharmaceutical composition using a carrier or base material in admixture with an effective amount of a therapeutic agent or medicament. The unique composition of the base materials can be used for "one-a-day" controlled release tablets of zero order containing various medicaments. The sustained release composition can be formed into a lozenge, tablet or suppository. Because of its properties, the composition can also be used as a base composition in tablets fox biaxial administration.
BACKGROUND OF THE INVENTION
The advantages of long-acting or sustained release products are well-known. Such products are of great value in the pharmaceutical field because medication can be administered for uniform and continuous release over a prolonged period of time to achieve a stable and desired blood level of the active ingredient without requiring frequent administration of the medicamentO The sustained release composition must meet certain criteria, namely it must provide uniform and constant dissolution and efficacy for a prolonged period of time, it must be easy to prepare, it must have acceptable taste and must be adaptable for use with a variety of therapeutic agents.
The use of cellulosic materials such as hydroxypropyl methyl cellulose as an ingredient in pharmaceutical formulations is known. For example, .
Z2~S5~
US. Patent No. 3,590,117 describes the use of hydroxypropyl methyl cellulose in long lasting torches used as vehicles for administering active medicaments. US. Patent No.
3,870,790, describes mixing an active therapeutic ingredient with a copolymer of premoisturized hydroxypropyl methyl cellulose powder optionally mixed with ethyl cellulose powder. The release period of the active medicament is a function of the moisture content of the cellulose carrier.
In US. Patent No. 4,259,314 there is described compositions which employ hydroxypropyl methyl cellulose of different viscosity grades and hydroxypropyl cellulose in a dry powder composition which has particular value for use with hydroscopic active ingredients.
US. Patent No. 4,292,299 to Suzuki et at.
describes a long-acting biaxial preparation which includes an adhesive outer layer comprising polymers which have adhesiveness to a wet mucous surface and which swell upon moistening together with a nonadhesive layer which is water soluble or water disintegrable. At least one of the layers is made to contain the active ingredient. The polymers suggested for use in the adhesive layer include homopolymers of acrylic acid monomers such as polyacrylic acid and related salts.
None of the compositions described in the prior art have demonstrated completely satisfactory properties for the administration of large active ingredient molecules. In particular the prior art compositions have not satisfactorily solved the problem of administering such molecules via resorption from the composition in the biaxial I
~Z2~55~
pouch of the mouth. Nor have the prior art compositions demonstrated completely satisfactory characteristics where it is desired to administer active ingredients over a 12 to 24 hour time period.
OBJECTS OF THE INVENTION
_ It is accordingly an object of the invention to provide a controlled, long-acting pharmaceutical composition for effective administration of therapeutic agents.
It is another object of the invention to provide a new base material or carrier which can be used in admixture with a variety of therapeutic agents and which can also be easily and inexpensively manufactured.
It is a further object to provide a method for producing a controlled, long-acting pharmaceutical composition which can be used for administering large active ingredient molecules.
It is still a further object of the invention to provide a method and composition for preparing a sustained release pharmaceutical formulation which can be used to administer large molecules of active ingredient via the biaxial pouch of the mouth.
It is yet a further object of the invention to provide a method and composition for preparing a sustained release pharmaceutical formulation which can be used to administer active ingredients over a 12 to 24 hour time frame, i.e., a so-called "zero order" sustained release composition.
us Other objects of the invention will be apparent from the following discussion.
GENERAL DESCRIPTION
These and other objects of the invention are achieved by using a carrier prepared from at least three components. Broadly, the carrier is comprised of:
(a) 5.5-98.5~ by weight of hydroxypropyl methyl cellulose;
(b) 0.25-4.5~ by weight of : hydroxypropyl cellulose; and (c) 1-90% by weight of a carboxyvinyl polymer.
Desirably, the carrier is comprised of:
(a) 10-80~ by weight of hydroxypropyl methyl cellulose;
(b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75~ by weight of a carboxyvinyl polymer.
In preferred form the carrier is comprised of:
(a) 2-35% by weight of hydroxypropyl methyl cellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20C;
(b) 3-85% by weight of hydroxypropyl methylcellulvse having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20C; and 12~gSSl (c) 2-40~ by weight of hydroxypropyl methyl cellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20 C;
(do 0.5-40~ by weight of hydroxpropyl methyl cellulose having a viscosity of about 100,000 centipoise for a I aqueous solution at 20 C;
(e) 0.25 to 4.5% by weight of hydroxypropyl cellulose; and f) 1 to 90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0~ by weight neutralized solution.
Preferably the hydroxypropyl cellulose which is used has a viscosity of 1000 to 4500 when measured as a 2% by weight aqueous solution.
Hydroxypropyl methyl cellulose having viscosities of 50 and 4000 centipoise for I aqueous solutions at 20C
are known and commercially available as Methuselah Eye and EM respectively (Dow Chemical Company registered trademarks). Hydroxypropyl methyl cellulose having viscosities of 15,000 and 100,000 centipoise for I aqueous solutions at 2Q C are known and commercially available as Methuselah K-15M and Loom respectively (Dow Chemical Company registered trademarks). Hydroxypropyl cellulose as used in accordance with the invention is known and commercially available as Closely (a Hercules Inc. registered trademark).
~ZZ~S5~
The carboxyvinyl polymers used in the invention are acrylic acid polymers cross linked with a polyalkenyl polyether. The polymers are available from the BY Goodrich Company under the trademark Carbopol. They have viscosities of 30,000-40,000 centipoise for 3% aqueous solutions. The polymer is a weak acid and reacts to form salts. Therein lies their efficacy in providing 2 zero order release rate under the alkaline conditions found in the small intestine.
The mixtures of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and polyacrylic acid are prepared in a straightforward method. The several components are added in the desired proportions to one another and thoroughly mixed to form a uniform composition. Thereafter from 2 to 700 my of an active ingredient are added to the carrier and the pharmaceutical composition is compressed and shaped into a convenient pharmaceutical form. Depending upon the conditions under which the material is compressed and further depending on the relative proportions of the several components, one obtains a product of unique sustained release characteristic. The sustained release characteristic of the composition can be predetermined and varied by adjusting the makeup of the composition within the aforesaid limits and/or by adjusting the compression of the tablet.
If the pharmaceutical composition is compressed under low pressure, a trash or biaxial tablet can be prepared capable of being sucked or used in the mouth. A
controlled release of the active therapeutic agent which is -~2;~955~
mucosally absorbed into the blood stream is achieved. If higher pressures are used to compress the pharmaceutical material a harder and longer-lasting pharmaceutical composition can be prepared suitable for rectal or vaginal application or suitable for swallowing in the form of a tablet. The final products may additionally contain adjutants such as coloring agents, flavoring agents, synthetic sweetening agents and preservatives.
To make the absorption of large molecules through the biaxial pouch possible, a sweetening agent like saccharin, cyclamate, Aspartame, or any other chemical which is at least 30 times as sweet as sugar is added to the base material in a quantity of 2 my or more.
The pharmaceutical compositions obtained using the dry carrier base material of the invention have controlled, long-acting capability so that therapeutically active agents can be uniformly and continuously released over prolonged periods of time ranging from about 2 to 24, or more, hours.
The duration, uniformity and continuity of release Or the therapeutically active ingredient can be suitably controlled by varying the relative amounts of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and carboxyvinyl polymer and/or by changing the surface of the finished product. The dry pharmaceutical formulation of the invention has considerable flexibility and versatility depending upon the form in which it is administered and the particular nature of the active therapeutic agent combined with the dry carrier base material.
~Z29SS~
Examples In each of the following examples the carrier composition defined was prepared by mixing the several components in the desired proportion in a mixing bowl. The mixture was thoroughly stirred to achieved uniformity and thereafter the desired amount of active ingredient and other adjutants were added in the amounts indicated.
The carrier, excipients and active ingredients were then thoroughly mixed and thereafter compressed into tablets at a compression of from 6 to 10 kg./cm2.
Base Composition Weight in Percent EX~lPLE I
Pseudephedrine Hal 120 my E-4M55 my 73.3333%
K-15M15 " 20.0000%
Closely 3 " 4.0000%
Carbopol 2 " 2.6667%
EXAMPLE II
-Hexocyclium methyl sulfate 50 my E-4M42.5 ") K-15M5.0 ") 98.5%
K-100~1 1.75 ") Carbopol .5 lo Closely . 25 " 0.5%
~955~l Base Composition Weight in Percent EXAMPLE III
Procainamide HCL250 my E-5012.5 " 9.6525%
EM 80 " 61.7761%
K-15M 30 " 23.1660%
Carbopol 5 n 3.8610%
Closely " 1.5444%
EXAMPLE IV
Ethaverine HCL150 my K-15M 6.75 " 4.5%
Clime " 1.0%
Carbopol 135 " 90.0~
Closely n 4.5%
EXAMPLE V
Imipramine HCL50 my EM 30 " 52.6316%
Clime 15 l 26.3158%
Carbopol10 " 17.5438 Closely 2 " 3.5088 EXAMPLE VI
Ferrous fumarate320 my K-15M 120 " 69.3641 Lomb 25 " 14.4509%
Xlucel 3 " 1.7341~
Carbopol 25 " 14.4509%
_ g _ of I
Base Composition Weight in Percent EXAMPLE VII
-Dextrometorphan BRIE 15 my (lozenge) E-4M13.5 3.8849%
Minutely Hexanitrate 320 "92.0863~
Carbopol 13.5 " 3.8849%
Closely 0.5 " 0.1439%
EXAMPLE VIII
Hydralazine HAL 100 my E-4M75 " 72.1154%
Clime 20 " 19.2308%
Closely 4 " 3.8461%
Carbopol 5 " 4.8077%
: EXAMPLE IX
Indomethacin75 my E-4M40 " 53.33%
X-15M 25 n 33.33~
Closely 3 " 4.00%
Carbopol 7 " 9,33%
~ZZ~55~
Base Composition Weight in Percent EXAMPLE X
_ - Meprobamate 400 my E-5070 " 34.3137%
X-15M80 " 39.2157 Clime 30 " 14,7059%
Carbop~l 20 " 9.8039%
Closely 4 " 1.9608%
EXAMPLE XI
SecGbarbital sodium 200 my (suppositories) K-15M130 " 19.9386%
Loom 80 " 12.2700%
Carbopol 40 " 6.1350%
Lucille 2 " .3067%
Excipients 400 " 61.3497%
EXAMPLE XII
Phenylpropanola~ine 75 my E-4M30 " 38.4615%
R-15M20 " 25.6410~
Clime 10 " 12.8205%
Carbopol 15 n 19.2308%
Closely 3 " 3.8462%
The novel carriers of the invention can be used with a wide variety of active therapeutic agents. The ~L~2~335Sl improved long acting compositions can be used, without limitation, as cardiovascular anti-inflammatories, analgesics, antiarrhymetics, bronchodilators, tranquilizers, calcium blockers, beta-blockers, decongestants, antispasmodic, weight control, antacids, cold and allergy products, and sedatives. It will be well understood by those skilled in the art that certain equivalents of each as shown may be employed and it will be recognized that various modifications are possible within the scope of the invention as defined in the following claims.
Claims (22)
1. A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
2. A sustained release pharmaceutical carrier as defined in claim 1 wherein the hydroxypropyl cellulose has a viscosity in the range of 1,000 to 1,500 centipoise for a 2%
aqueous solution at 25°C.
aqueous solution at 25°C.
3. A sustained release pharmaceutical carrier as defined in claim 1 adapted for facilitating the absorption of large molecules through the buccal pouch of the mouth containing a sweetening agent at least 30 times as sweet as sugar.
4. A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
(a) 10-80% by weight of hydroxypropyl methylcellulose;
(b) 1.0-3.5% by weight of hydroxypropyl cellulose;
(c) 3-75% by weight of a carboxyvinyl polymer.
(a) 10-80% by weight of hydroxypropyl methylcellulose;
(b) 1.0-3.5% by weight of hydroxypropyl cellulose;
(c) 3-75% by weight of a carboxyvinyl polymer.
5. A sustained release pharmaceutical carrier suitable for admixture with active ingredients and particularly adapted for preparation of compositions suitable for administration of active ingredients through the buccal pouch of the mouth which comprises:
(a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20°C;
(b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20°C; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C;
(d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C;
(e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
(a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20°C;
(b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20°C; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C;
(d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C;
(e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
6. A sustained release pharmaceutical carrier as defined in claim 5 wherein the hydroxypropyl cellulose has a viscosity in the range of 1,000 to 1,500 centipoise for a 2%
aqueous solution at 25° C.
aqueous solution at 25° C.
7. A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising:
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
8. A sustained release pharmaceutical carrier as defined in claim 7 adapted for facilitating the absorption of large molecules through the buccal pouch of the mouth containing a sweetening agent at least 30 times as sweet as sugar.
9. A sustained release pharmaceutical carrier as defined in claim 7 which is zero order with respect to its release of active ingredient.
10. A sustained release pharmaceutical carrier as defined in claim 7 which is adapted for use in a one-a-day tablet.
11. A sustained release pharmaceutical composition as defined in claim 7 wherein the said therapeutic agent is present in from 0.25 to 700 mg.
12. A sustained release pharmaceutical composition as defined in claim 7 wherein the carrier contains hydroxypropyl cellulose having a viscosity of 1,000 to 1,500 centipoise for a 2% aqueous solution at 25° C.
13. A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising:
(a) 10-80% by weight of hydroxypropyl methylcellulose;
(b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75% by weight of a carboxyvinyl polymer.
(a) 10-80% by weight of hydroxypropyl methylcellulose;
(b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75% by weight of a carboxyvinyl polymer.
14. A sustained release pharmaceutical composition adapted for administration via the buccal pouch of the mouth which comprises a sustained release carrier and an active therapeutic agent, said carrier comprising:
(a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20°C;
(b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20°C; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C;
(d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C;
(e) 0.25-4.5% by weight of hydroxy-propyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
(a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20°C;
(b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20°C; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C;
(d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C;
(e) 0.25-4.5% by weight of hydroxy-propyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
15. A sustained relase pharmaceutical composition as defined in claim 8 wherein said therapeutic agent is present in an amount of 0.25 to 700 mg.
16. A sustained release pharmaceutical composition as defined in claim 8 wherein the hydroxypropyl cellulose has a viscosity of 1,000 to 1,500 for a 2% aqueous solution at 25° C
17. A sustained release pharmaceutical carrier according to claim 1, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
18. A sustained release pharmaceutical carrier according to claim 4, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
19. A sustained release pharmaceutical carrier according to claim 5, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
20. A sustained release pharmaceutical composition according to claim 7, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
21. A sustained release pharmaceutical composition according to claim 13, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
22. A sustained release pharmaceutical composition according to claim 14, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/556,844 US4680323A (en) | 1983-12-01 | 1983-12-01 | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
| US556,844 | 1983-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1229551A true CA1229551A (en) | 1987-11-24 |
Family
ID=24223083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000469018A Expired CA1229551A (en) | 1983-12-01 | 1984-11-30 | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4680323A (en) |
| JP (1) | JPS60185728A (en) |
| KR (1) | KR930000046B1 (en) |
| AT (1) | AT394948B (en) |
| AU (1) | AU572571B2 (en) |
| BE (1) | BE901186A (en) |
| CA (1) | CA1229551A (en) |
| CH (1) | CH664970A5 (en) |
| DE (1) | DE3443587C2 (en) |
| DK (1) | DK162511C (en) |
| EG (1) | EG17134A (en) |
| FI (1) | FI82601C (en) |
| FR (1) | FR2555901B1 (en) |
| GB (1) | GB2152940B (en) |
| HU (1) | HU193717B (en) |
| IE (1) | IE58112B1 (en) |
| IL (1) | IL73594A (en) |
| IT (1) | IT1177152B (en) |
| LU (1) | LU85660A1 (en) |
| MX (1) | MX161165A (en) |
| NL (1) | NL193164C (en) |
| NO (1) | NO167002C (en) |
| NZ (1) | NZ210310A (en) |
| PT (1) | PT79427B (en) |
| SE (1) | SE461071B (en) |
| ZA (1) | ZA849373B (en) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK62184D0 (en) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | DIFFUSION COATED POLYDEPOT PREPARATION |
| DE3586600T2 (en) * | 1984-02-10 | 1993-02-18 | Benzon Pharma As | DOSAGE CONTAINING A VARIETY WITH A DIFFERENTIAL COVERED UNITS. |
| JPS6185315A (en) * | 1984-10-04 | 1986-04-30 | Teikoku Seiyaku Kk | Sheet-like preparation |
| JPS61286330A (en) * | 1985-06-11 | 1986-12-16 | Teijin Ltd | Slow-releasing medicinal preparation for oral administration |
| DE3681348D1 (en) * | 1985-06-11 | 1991-10-17 | Teijin Ltd | ORAL DRUG PREPARATION WITH RETARDIVE EFFECT. |
| GB8518927D0 (en) * | 1985-07-26 | 1985-09-04 | Vincent Processes Ltd | Tablets |
| US4704285A (en) * | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
| JPS62120315A (en) * | 1985-11-20 | 1987-06-01 | Shin Etsu Chem Co Ltd | Production of sustained release tablet |
| IL85538A (en) * | 1987-02-27 | 1991-09-16 | Lilly Co Eli | Sustained release matrix tablet formulations containing hydrophilic and enteric polymers |
| US4783331A (en) * | 1987-06-29 | 1988-11-08 | Miles Inc. | Method for solubilization of aspartame in effervescent aqueous systems; and composition |
| WO1989010745A1 (en) * | 1988-05-02 | 1989-11-16 | Pomerantz, Edwin | Compositions and in situ methods for forming films on body tissue |
| US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| JP2845342B2 (en) * | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | Vitamin D Lower 3 Derivative-Containing Solid Preparation Composition |
| US5876752A (en) * | 1990-08-07 | 1999-03-02 | Pfizer Inc. | Use of interfacially-polymerized membranes in delivery devices |
| US5498422A (en) * | 1991-04-08 | 1996-03-12 | Nippon Shinyaku Company Limited | Sustained release capsule |
| US5204116A (en) * | 1991-05-01 | 1993-04-20 | Alza Corporation | Dosage form providing immediate therapy followed by prolonged therapy |
| EP0550108B1 (en) * | 1991-12-30 | 1998-03-18 | Akzo Nobel N.V. | Sustained release thyroactive composition |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| DE4341156C2 (en) * | 1993-12-02 | 1997-11-13 | Wacker Chemie Gmbh | Use of water-redispersible plastic dispersion powders as drug carriers |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| JP3707798B2 (en) * | 1996-05-13 | 2005-10-19 | ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム | Intraoral drug delivery system |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| US6479082B1 (en) | 1996-12-23 | 2002-11-12 | Wm. Wrigley, Jr. Co. | Process of increasing flavor release from chewing gum using hydroxypropyl cellulose and product thereof |
| CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
| US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| WO1999024017A1 (en) * | 1997-11-12 | 1999-05-20 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 | Novel oral dosage form for carvedilol |
| JP2002532551A (en) * | 1998-12-22 | 2002-10-02 | ノボ ノルディスク アクティーゼルスカブ | New formulation |
| US6207682B1 (en) | 1998-12-22 | 2001-03-27 | Novo Nordisk A/S | Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| DE60037799D1 (en) | 1999-04-01 | 2008-03-06 | Wrigley W M Jun Co | STRUCTURES WITH LONG-LASTING FLAVOR FOR CHEESE |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
| US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
| US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
| WO2002045695A2 (en) | 2000-12-05 | 2002-06-13 | Alexander Macgregor | Hydrostatic delivery system for controlled delivery of agent |
| US20030044462A1 (en) * | 2001-08-20 | 2003-03-06 | Kali Laboratories, Inc. | Sustained release tablets containing bupropion hydrochloride |
| US20030167556A1 (en) * | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
| WO2004037228A1 (en) * | 2002-10-22 | 2004-05-06 | Ranbaxy Laboratories Limited | Sustained release compositions containing alfuzosin |
| US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
| US20060057165A1 (en) * | 2004-09-10 | 2006-03-16 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
| EP1817043A4 (en) | 2004-11-02 | 2010-01-27 | Chr Hansen As | Encapsulated bacteriophage formulation |
| BRPI0614949A2 (en) * | 2005-08-23 | 2011-04-26 | Nissan Chemical Ind Ltd | sustained release preparation |
| RU2008124109A (en) * | 2005-12-08 | 2010-01-20 | МДРНА, Инк. (US) | TRANSMISSION DELIVERY OF STABILIZED EXCENDIN COMPOSITIONS |
| US20070185035A1 (en) * | 2005-12-23 | 2007-08-09 | Nastech Pharmaceutical Company Inc. | Enhanced mucosal administration of neuroprotective peptides |
| US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20080206333A1 (en) * | 2007-01-31 | 2008-08-28 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20090197824A1 (en) * | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| WO2008102235A1 (en) * | 2007-02-20 | 2008-08-28 | Aurobindo Pharma Limited | Controlled release formulations of alfuzosin |
| US20090042795A1 (en) * | 2007-06-05 | 2009-02-12 | Pasan Fernando | Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation |
| KR100836960B1 (en) * | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | A novel controlled release-niacin formulation |
| US7928189B2 (en) * | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
| WO2009143072A1 (en) * | 2008-05-19 | 2009-11-26 | Wynden Pharmaceuticals, Inc. | High-loading, controlled-release magnesium oral dosage forms and methods of making and using same |
| US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| EP3364955B1 (en) | 2015-10-09 | 2022-04-20 | RB Health (US) LLC | Pharmaceutical formulation |
| CN115429815B (en) * | 2021-06-02 | 2023-12-22 | 广州帝奇医药技术有限公司 | Long-acting satiety composition, preparation method and application |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2887440A (en) * | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
| US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| US3138524A (en) * | 1962-06-06 | 1964-06-23 | Hoffmann La Roche | Pharmaceutical suspensions |
| US3428728A (en) * | 1965-10-21 | 1969-02-18 | Hans Lowey | Timed release sublingual medications |
| GB1171691A (en) * | 1967-02-24 | 1969-11-26 | Forest Laboratories | Lond-Acting Oral Carrier |
| US3590117A (en) * | 1969-03-24 | 1971-06-29 | Richardson Merrell Inc | Long-lasting troche containing guar gum |
| GB1279214A (en) * | 1970-01-22 | 1972-06-28 | Forest Laboratories | Long-acting oral carrier |
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| CA945899A (en) * | 1971-09-16 | 1974-04-23 | Hans Lowey | Long-acting oral carrier |
| CA1018456A (en) * | 1972-06-26 | 1977-10-04 | Hans Lowey | Prolonged release lozenges |
| US3876771A (en) * | 1973-09-04 | 1975-04-08 | Hallister Inc | Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid |
| YU43437B (en) * | 1976-05-05 | 1989-08-31 | Lowey Hans | Process for obtaining tablets containing an active component with long lasting effect |
| JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
| JPS55118414A (en) * | 1979-03-05 | 1980-09-11 | Teijin Ltd | Prolonged release drug and its preparation |
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
| US4357469A (en) * | 1979-06-14 | 1982-11-02 | Forest Laboratories, Inc. | Carrier base material for prolonged release therapeutic compositions |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| JPS58192817A (en) * | 1982-05-06 | 1983-11-10 | Nippon Soda Co Ltd | Production of stick-like drug preparation |
| CA1208558A (en) * | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
| US4540566A (en) * | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
-
1983
- 1983-12-01 US US06/556,844 patent/US4680323A/en not_active Expired - Lifetime
-
1984
- 1984-10-19 AU AU34499/84A patent/AU572571B2/en not_active Expired
- 1984-10-26 NO NO844280A patent/NO167002C/en not_active IP Right Cessation
- 1984-10-30 PT PT79427A patent/PT79427B/en unknown
- 1984-11-09 IT IT23523/84A patent/IT1177152B/en active
- 1984-11-19 NL NL8403522A patent/NL193164C/en not_active IP Right Cessation
- 1984-11-22 IL IL73594A patent/IL73594A/en not_active IP Right Cessation
- 1984-11-23 NZ NZ210310A patent/NZ210310A/en unknown
- 1984-11-27 FI FI844656A patent/FI82601C/en active IP Right Grant
- 1984-11-28 GB GB08430083A patent/GB2152940B/en not_active Expired
- 1984-11-29 FR FR8418208A patent/FR2555901B1/en not_active Expired
- 1984-11-29 DE DE3443587A patent/DE3443587C2/en not_active Expired
- 1984-11-29 JP JP59252782A patent/JPS60185728A/en active Pending
- 1984-11-30 IE IE307784A patent/IE58112B1/en not_active IP Right Cessation
- 1984-11-30 CA CA000469018A patent/CA1229551A/en not_active Expired
- 1984-11-30 DK DK569784A patent/DK162511C/en not_active IP Right Cessation
- 1984-11-30 CH CH5728/84A patent/CH664970A5/en not_active IP Right Cessation
- 1984-11-30 AT AT0382484A patent/AT394948B/en not_active IP Right Cessation
- 1984-11-30 ZA ZA849373A patent/ZA849373B/en unknown
- 1984-11-30 HU HU844438A patent/HU193717B/en not_active IP Right Cessation
- 1984-11-30 KR KR1019840007568A patent/KR930000046B1/en not_active IP Right Cessation
- 1984-11-30 LU LU85660A patent/LU85660A1/en unknown
- 1984-11-30 MX MX203541A patent/MX161165A/en unknown
- 1984-11-30 SE SE8406081A patent/SE461071B/en not_active IP Right Cessation
- 1984-11-30 BE BE0/214099A patent/BE901186A/en not_active IP Right Cessation
- 1984-12-01 EG EG733/84A patent/EG17134A/en active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1229551A (en) | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration | |
| US5686094A (en) | Controlled release formulations for the treatment of xerostomia | |
| US5102666A (en) | Calcium polycarbophil controlled release composition and method | |
| US4250163A (en) | Method and preparation for administration to the mucosa of the oral or nasal cavity | |
| US4259314A (en) | Method and composition for the preparation of controlled long-acting pharmaceuticals | |
| US4715369A (en) | Method of treating an injured part on the oral mucosa and the covering material for use thereof | |
| US5314915A (en) | Bioadhesive pharmaceutical carrier | |
| US4478822A (en) | Drug delivery system utilizing thermosetting gels | |
| US5330761A (en) | Bioadhesive tablet for non-systemic use products | |
| US4767787A (en) | Sheet-shape adhesive preparation | |
| JP3069458B2 (en) | Orally disintegrating tablet and production method thereof | |
| EP0126684B1 (en) | Drug delivery system utilizing thermosetting gels | |
| US20010006677A1 (en) | Effervescence polymeric film drug delivery system | |
| JPH0729915B2 (en) | Sheet-shaped oral patch | |
| JP3064417B2 (en) | Controlled release formulations and methods | |
| JPS6222713A (en) | Mucosa adherent preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |